Natus Medical (BABY) Updates Q1 2019 Earnings Guidance

Natus Medical (NASDAQ:BABY) issued an update on its first quarter 2019 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.01-0.08 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.31. The company issued revenue guidance of $111-115 million, compared to the consensus revenue estimate of $131.3 million.Natus Medical also updated its FY 2019 guidance to $1.12-1.49 EPS.

Shares of NASDAQ:BABY traded down $3.72 during midday trading on Wednesday, reaching $26.15. 106,235 shares of the company’s stock were exchanged, compared to its average volume of 429,990. The company has a current ratio of 2.62, a quick ratio of 1.89 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of 17.91 and a beta of 0.58. Natus Medical has a fifty-two week low of $27.69 and a fifty-two week high of $37.95.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, February 13th. The medical equipment provider reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.06). The business had revenue of $141.00 million for the quarter, compared to analyst estimates of $135.80 million. Natus Medical had a positive return on equity of 11.34% and a negative net margin of 3.53%. The firm’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.42 earnings per share. As a group, equities research analysts predict that Natus Medical will post 1.49 earnings per share for the current fiscal year.

BABY has been the subject of a number of recent analyst reports. Roth Capital set a $36.00 price objective on Natus Medical and gave the stock a buy rating in a research report on Thursday, October 25th. Zacks Investment Research cut Natus Medical from a hold rating to a strong sell rating in a report on Friday, October 26th. ValuEngine cut Natus Medical from a hold rating to a sell rating in a report on Saturday, November 10th. BidaskClub upgraded Natus Medical from a hold rating to a buy rating in a report on Wednesday, November 21st. Finally, William Blair restated a market perform rating on shares of Natus Medical in a report on Saturday, January 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $36.00.

In related news, Director Robert A. Gunst sold 14,750 shares of the business’s stock in a transaction that occurred on Monday, November 19th. The stock was sold at an average price of $33.54, for a total transaction of $494,715.00. Following the completion of the sale, the director now owns 32,392 shares in the company, valued at $1,086,427.68. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ken Ludlum sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $31.02, for a total value of $930,600.00. Following the sale, the director now owns 73,957 shares of the company’s stock, valued at approximately $2,294,146.14. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

WARNING: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at

About Natus Medical

Natus Medical Incorporated provides newborn care, neurology, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

See Also: How to calculate compound interest

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit